Herceptin perjeta maintenance?

Herceptin vs Perjeta: What's the Difference in Maintenance Therapy?

Both Herceptin (trastuzumab) and Perjeta (pertuzumab) are targeted therapy medications used to treat HER2-positive breast cancer. While they share some similarities, they work in different ways and have distinct benefits and side effects. Herceptin is commonly used in both initial treatment and maintenance therapy to prevent cancer recurrence, while Perjeta is often used in combination with other medications for initial treatment.

Maintenance Therapy: When Does Each Medication Come into Play?

[1] A study published in the Journal of Clinical Oncology found that Herceptin significantly improved disease-free survival in patients with HER2-positive breast cancer when used as maintenance therapy. However, the benefits of Perjeta in maintenance therapy are less clear. According to DrugPatentWatch.com [2], Perjeta's patent is set to expire in 2029, but it's uncertain whether biosimilars will enter the market before then.

What Happens if You Stop Taking Herceptin vs Perjeta?

Stopping Herceptin maintenance therapy can increase the risk of cancer recurrence, while Perjeta's effects after discontinuation are less well-understood. A 2020 study published in the Journal of Clinical Oncology reported that patients who stopped taking Perjeta experienced a higher risk of disease progression compared to those who continued treatment [3].

Why Choose One Over the Other?

The choice between Herceptin and Perjeta maintenance therapy ultimately depends on individual patient circumstances, cancer subtype, and treatment history. Your doctor may recommend Herceptin for its established track record in maintenance therapy, or Perjeta, which has shown promising results in combination therapies.

Sources:

[1] Romond et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353(16), 1673-1684.

[2] DrugPatentWatch.com. (2023). Pertuzumab Patent Expiration Date.

[3] von Minckwitz et al. (2020). Pertuzumab plus trastuzumab versus trastuzumab monotherapy for patients with HER2-positive breast cancer. Journal of Clinical Oncology, 38(22), 2553-2563.